8-K: Femasys Expands FemBloc in Europe with Second Partner Order

Femasys Inc. announced a significant initial order for its FemBloc permanent birth control solution, expanding its presence in France and the Benelux region.

Summary

• Femasys Inc. secured a second partner order for its FemBloc Permanent Birth Control in Europe.
• The initial order is valued at approximately $500,000 USD for the commercial launch in France and the Benelux region.
• The partnership is with Kebomed, a leading independent distributor of medical devices across Europe.
• This order marks continued progress in expanding FemBloc's presence across key European markets, following the company's recent entry into Spain.
• FemBloc is a first-of-its-kind, non-surgical permanent contraceptive solution.
• FemBloc received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025.

Sentiment

Score: 8

Explanation: The filing announces a significant commercial milestone with a substantial initial order and expansion into new European markets for a breakthrough product, indicating strong positive momentum and future growth potential.

Positives

• Secured a significant initial order valued at approximately $500,000 USD for FemBloc, indicating strong commercial traction.
• Expanded commercial presence into France and the Benelux region, following entry into Spain, demonstrating successful execution of global growth strategy.
• Established a strategic partnership with Kebomed, a leading independent distributor with deep expertise in European market access and women's health.
• FemBloc is a first-of-its-kind, non-surgical permanent birth control solution addressing a significant unmet need in women's reproductive health.
• FemBloc avoids the risks of infection and other surgical complications associated with traditional surgical sterilization, offering a safer, more convenient, and affordable option.
• FemBloc has received full regulatory approval in Europe (June 2025), the UK (August 2025), and New Zealand (September 2025).
• Published clinical trial data for FemaSeed, another Femasys product, demonstrates it is over twice as effective as traditional IUI with a comparable safety profile.
• Published data from initial clinical trials for FemBloc demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.

Risks

• Ability to obtain regulatory approvals for the FemBloc product candidate.
• Ability to develop and advance the current FemBloc product candidate and successfully enroll and complete the clinical trial.
• The ability of clinical trials to demonstrate safety and effectiveness of the product candidate and other positive results.
• Estimates regarding the total addressable market for products and product candidates may not be accurate.
• Ability to commercialize products and product candidates.
• Ability to establish, maintain, grow, or increase sales and revenues.
• Effect of delays in commercializing products, including FemaSeed.
• Business model and strategic plans for products, technologies, and business, including the implementation thereof.
• Other risks and uncertainties described in the 'Risk Factors' section of the Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC.

Future Outlook

Femasys is well positioned to create lasting impact for patients and long-term value for shareholders through international expansion driven by strategic partnerships. Enrollment in the FINALE pivotal trial (NCT05977751) for U.S. FDA approval of FemBloc is ongoing.

Management Comments

• "Our selection of European partners, such as Kebomed, has been deliberate and strategic, ensuring both deep expertise in market access and a shared commitment to advancing women's healthcare." Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc.
• "The initial orders reflect confidence in FemBloc's potential to transform reproductive health." Kathy Lee-Sepsick.
• "With these partnerships driving our international expansion, Femasys is well positioned to create lasting impact for patients and long-term value for shareholders." Kathy Lee-Sepsick.
• "We are pleased to partner with Femasys to bring FemBloc to women in France and Benelux." Sren Dalmark Kornerup, Chairman of Kebomed Europe AG.
• "For several years, there has been a void in permanent contraception options, with no new advancements to meet the clear demand from both women and physicians. FemBloc represents a revolutionary breakthrough that the market has been waiting for, and we are thrilled to be at the forefront of introducing this much-needed solution." Sren Dalmark Kornerup.

Industry Context

The announcement highlights a significant unmet need in women's reproductive health for non-surgical permanent birth control. FemBloc is positioned as a disruptive advancement with no comparable alternatives on the market, contrasting with centuries-old surgical sterilization methods. The partnership with Kebomed, a pan-European distributor with a strong focus on women's health, reinforces Femasys' strategic approach to penetrate key European markets where demand for such innovations is high, aligning with broader trends towards less invasive medical procedures.

Comparison to Industry Standards

• FemBloc is described as a "first-of-its-kind, non-surgical solution for permanent birth control," indicating it has no direct comparable alternatives currently on the market.
• It offers significant advantages over "surgical sterilization" by requiring no anesthesia, no incisions, and no recovery time, while avoiding the risks of infection and other surgical complications.
• FemaSeed Intratubal Insemination is stated to be "over twice as effective as traditional IUI" with a comparable safety profile, demonstrating superior performance in its category.

Stakeholder Impact

• Shareholders: Potential for long-term value creation due to successful international expansion and commercialization of a disruptive product.
• Patients (Women): Gaining access to a safer, more convenient, and affordable non-surgical permanent birth control option, addressing a significant unmet need.
• Physicians: Provided with a revolutionary breakthrough solution for permanent contraception, enhancing treatment options for patients.
• Distributors (Kebomed): Strengthens their product portfolio in women's health, reinforcing their leadership and deep clinical expertise in this therapeutic area.

Next Steps

• Continued commercialization of FemBloc through strategic partnerships in select European countries.
• Ongoing enrollment in the FINALE pivotal trial (NCT05977751) for U.S. FDA approval of FemBloc.

Key Dates

Recommendation

The announcement details a significant commercial milestone with a $500,000 initial order for FemBloc, expanding its market reach into France and Benelux. This indicates strong market acceptance and execution of the company's global growth strategy for a "first-of-its-kind" non-surgical permanent contraceptive solution. With regulatory approvals already secured in Europe, UK, and New Zealand, and ongoing US FDA trials, the company is demonstrating clear progress in addressing a substantial unmet need in women's health. This positive commercial traction, coupled with the disruptive nature of the product, suggests significant future revenue potential and long-term value for shareholders, making it a strong buy.

Keywords

Femasys, FEMY, FemBloc, permanent birth control, contraception, women's health, medical devices, Europe, France, Benelux, Kebomed, non-surgical, reproductive health, medical technology